Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.51 |
| ▸ | PPARA | Q07869 | 5/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | TERT | O14746 | 3/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | PPARD | Q03181 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | FABP4 | P15090 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5452957 | 1.00 | PPARG (0.51) | PPARGPPARACNR1CNR2TERT | |
| SCHEMBL864034 | 1.00 | PPARG (0.51) | PPARGPPARACNR1CNR2TERT | |
| SCHEMBL2342147 | 1.00 | PPARG (0.51) | PPARGPPARACNR1CNR2TERT | |
| SCHEMBL3710792 | 1.00 | PPARG (0.51) | PPARGPPARACNR1CNR2TERT | |
| SCHEMBL11743976 | 1.00 | PPARG (0.51) | PPARGPPARACNR1CNR2TERT | |
| SCHEMBL14672999 | 1.00 | PPARG (0.51) | PPARGPPARACNR1CNR2TERT | |
| SCHEMBL874683 | 1.00 | PPARG (0.51) | PPARGPPARACNR1CNR2TERT | |
| SCHEMBL347470 | 1.00 | PPARG (0.51) | PPARGPPARACNR1CNR2TERT | |
| SCHEMBL22555434 | 1.00 | PPARG (0.51) | PPARGPPARACNR1CNR2TERT | |
| SCHEMBL22555479 | 1.00 | PPARG (0.51) | PPARGPPARACNR1CNR2TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 971 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589377-B2 | Encapsulated composition comprising core-shell microcapsules and process for its preparation | GIVAUDAN SA (CH) | 2026-03-31 | — | — | US | claimed |
| EP-4695016-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2026-02-18 | — | — | EP | claimed |
| EP-4302747-B1 | SYSTEM FOR DISPENSING A COSMETIC PRODUCT | OREAL (FR) | 2026-01-14 | — | — | EP | claimed |
| EP-4655373-A1 | BIODEGRADABLE PERFUME COMPOSITION | Givaudan SA (CH) | 2025-12-03 | — | — | EP | claimed |
| WO-2025202258-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2025-10-02 | — | — | WO | claimed |
| US-12398341-B2 | Apparatus and compositions for improving scent delivery | THE PROCTER & GAMBLE COMPANY (US) | 2025-08-26 | — | — | US | claimed |
| US-20250163343-A1 | FRAGRANCE COMPOSITIONS FOR SLEEP IMPROVEMENT | INTERNATIONAL FLAVORES & FRAGRANCES INC. | 2025-05-22 | — | — | US | claimed |
| EP-3325588-B1 | PERFUME COMPOSITIONS | GIVAUDAN SA (CH) | 2025-04-16 | — | — | EP | claimed |
| US-12247180-B2 | Apparatus and compositions for improving scent delivery | THE PROCTER & GAMBLE COMPANY (US) | 2025-03-11 | — | — | US | claimed |
| US-12239209-B2 | System for dispensing a cosmetic product | L'OREAL (FR) | 2025-03-04 | — | — | US | claimed |
| CN-101496799-A | Method of treating skin with aromatic skin active ingredients | MARY KAY INC (US) | 2009-08-05 | — | — | CN | claimed |
| US-20080311054-A1 | Compositions and Methods to Counteract Oral Malodour | GIVAUDAN SA (CH) | 2008-12-18 | — | — | US | claimed |
| US-20080247966-A1 | Compositions and Methods to Counteract Oral Malodour | GIVAUDAN SA (CH) | 2008-10-09 | — | — | US | claimed |
| EP-1937365-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | Givaudan SA (CH) | 2008-07-02 | — | — | EP | claimed |
| EP-1919566-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | Givaudan SA (CH) | 2008-05-14 | — | — | EP | claimed |
| WO-2007025402-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | GIVAUDAN SA (CH) | 2007-03-08 | — | — | WO | claimed |
| WO-2007025401-A1 | COMPOSITIONS AND METHODS TO COUNTERACT ORAL MALODOUR | GIVAUDAN SA (CH) | 2007-03-08 | — | — | WO | claimed |
| CN-1361817-A | Perfume compositions | PROCTER & GAMBLE (US) | 2002-07-31 | — | — | CN | claimed |
| EP-1072673-A2 | Perfume compositions | THE PROCTER & GAMBLE COMPANY (US) | 2001-01-31 | — | — | EP | claimed |
| WO-2001005919-A2 | PERFUME COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2001-01-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311054-A1 | Compositions and Methods to Counteract Oral Malodour | TAS2R60, TAS2R40, LPO | PPARG 1697/4885PPARA 1164/4885CNR1 2649/4885 |
| US-12589377-B2 | Encapsulated composition comprising core-shell microcapsules and process for its preparation | CUTA, EXOC1, EXOSC10 | PPARG 3841/4885PPARA 4555/4885CNR1 2945/4885 |
| US-12239209-B2 | System for dispensing a cosmetic product | PDE12, SAMM50, POLR1C | PPARG 177/4885PPARA 476/4885CNR1 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.